目的:分析复发/难治原发性中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)患者临床特点并探讨其影响预后的因素,为临床诊疗提供依据。方法:选取复旦大学附属华山医院2006年10月至2015年8月确诊的64例复发/难治PCNS...目的:分析复发/难治原发性中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)患者临床特点并探讨其影响预后的因素,为临床诊疗提供依据。方法:选取复旦大学附属华山医院2006年10月至2015年8月确诊的64例复发/难治PCNSL患者的病例资料、治疗方案、实验室辅助检查指标进行回顾性分析。采用Cox回归多因素分析。结果:单因素和多因素分析结果显示,首次无疾病进展生存期(progression-free survival of first time,PFS1)≤1年、Karnofsky评分(Karnofsky performance score,KPS)<70分为影响复发/难治PCNSL预后的独立危险因素。PFS1≥1年患者中位第二次无疾病进展生存期(median progression-free survival of secondtime,mPFS2)和中位第二次总生存时间(median overall survival of second time,mOS2)分别为19个月和21个月,而PFS1<1年患者mPFS2和mOS2分别为10个月和14个月。复发/难治时KPS评分≥70分患者与KPS评分<70分患者mPFS2分别为40个月和10个月,mOS2分别为43个月和12个月。另外,单因素分析首次复发/难治PCNSL患者选用含有大剂量甲氨蝶呤(high-dose methotrexate,HD-MTX)化疗方案的mPFS2为18个月,而选用不含HD-MTX化疗方案的mPFS2为10个月,差异具有统计学意义。多因素分析结果显示,挽救方案为影响患者PFS的相关因素;单因素分析结果显示,挽救方案含有HD-MTX与不含有HD-MTX组的mOS2分别为23个月和12个月,差异无统计学意义,考虑与样本量较小有关。结论:PFS1≤1年、KPS评分<70分是影响复发/难治PCNSL预后的独立危险因素。首次复发/难治PCNSL患者挽救治疗继续给予HD-MTX为基础的化疗方案可能会提高患者的远期疗效。展开更多
Background:Diffuse large B-cell lymphoma(DLBCL)patients refractory to rituximab-based immunochemotherapy have a dismal prognosis.However,the definition of refractory DLBCL remains inconsistent and no large cohort stud...Background:Diffuse large B-cell lymphoma(DLBCL)patients refractory to rituximab-based immunochemotherapy have a dismal prognosis.However,the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries.To validate the definition and outcomes of refractory DLBCL in China,we conducted a multicenter,retrospective cohort study.Methods:The REtrospective AnaLysis of Treatment REspoNse of refractory DLBCL(REAL-TREND)study was performed using real-world data from 8 centers in China.DLBCL patients with curative intent were included in the REAL-TREND dataset.Overall survival(OS)was estimated using the Kaplan-Meier method and compared by the log-rank test.Due to heterogeneity in response rates among different centers,the response rates of refractory patients were pooled using random-effect models.Multivariate survival analysis was performed using the Cox regression model.Results:A total of 2778 DLBCL patients diagnosed between January,2010 and December,2015 were enrolled to this study.After validating previous definitions,the SCHOLAR-1 study was most suitable to define refractory DLBCL.The estimated 5-year cumulative incidence of refractory patients was 20%(95% confidence Interval[CI]=18%-22%).After the determination of refractory disease,overall response rate and complete remission rate were 30%(95%CI=22%-38%)and 9%(95%CI=4%-15%),respectively.Patients with either no response to immunochemotherapy or relapse within 12 months after stem-cell transplantation had inferior survival with a median OS of 5.9 months(95%CI=5.5-7.1 months)and 2-year OS rate of 16%(95%CI=12%-20%).International prognostic index score 4-5(hazard ratio[HR]=2.22;95%CI=1.47-3.35),central nervous systemrelapse(HR=1.43;95%CI=1.04-1.97),and best response status(HR=2.68;95%CI=1.42-5.03 for partial remission.HR=5.97,95%CI=3.21-11.11 for stable disease/progressive disease)were independent unfavorable prognostic factors.Conclusions:This is the first large-scale Asian cohort study focusing on outcomes of refractory DLBCL.The definition of the SCHOLAR-1 study identifies patients with homogenously inferior survival,thus is appropriate to select refractory DLBCL.Due to poor clinical outcomes in the rituximab era,patients with refractory DLBCL may be potential candidates for novel treatment modalities.展开更多
文摘目的:分析复发/难治原发性中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)患者临床特点并探讨其影响预后的因素,为临床诊疗提供依据。方法:选取复旦大学附属华山医院2006年10月至2015年8月确诊的64例复发/难治PCNSL患者的病例资料、治疗方案、实验室辅助检查指标进行回顾性分析。采用Cox回归多因素分析。结果:单因素和多因素分析结果显示,首次无疾病进展生存期(progression-free survival of first time,PFS1)≤1年、Karnofsky评分(Karnofsky performance score,KPS)<70分为影响复发/难治PCNSL预后的独立危险因素。PFS1≥1年患者中位第二次无疾病进展生存期(median progression-free survival of secondtime,mPFS2)和中位第二次总生存时间(median overall survival of second time,mOS2)分别为19个月和21个月,而PFS1<1年患者mPFS2和mOS2分别为10个月和14个月。复发/难治时KPS评分≥70分患者与KPS评分<70分患者mPFS2分别为40个月和10个月,mOS2分别为43个月和12个月。另外,单因素分析首次复发/难治PCNSL患者选用含有大剂量甲氨蝶呤(high-dose methotrexate,HD-MTX)化疗方案的mPFS2为18个月,而选用不含HD-MTX化疗方案的mPFS2为10个月,差异具有统计学意义。多因素分析结果显示,挽救方案为影响患者PFS的相关因素;单因素分析结果显示,挽救方案含有HD-MTX与不含有HD-MTX组的mOS2分别为23个月和12个月,差异无统计学意义,考虑与样本量较小有关。结论:PFS1≤1年、KPS评分<70分是影响复发/难治PCNSL预后的独立危险因素。首次复发/难治PCNSL患者挽救治疗继续给予HD-MTX为基础的化疗方案可能会提高患者的远期疗效。
基金by research funding from the National Natural Science Foundation of China(81670176 to L.W.,81520108003,and 81830007 to W.Z.)the Chang Jiang Scholars Program(T2015055 to W.Z.)+4 种基金the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support(20152206 to L.W.and 20152208 to W.Z.)the Clinical Research Plan of SHDC(SHDC2020CR1032B to W.Z.)the Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine(DLY201601 to W.Z.)the Collaborative Innovation Center of Systems Biomedicine(to W.Z.)the Samuel Waxman Cancer Research Foundation(to W.Z.).
文摘Background:Diffuse large B-cell lymphoma(DLBCL)patients refractory to rituximab-based immunochemotherapy have a dismal prognosis.However,the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries.To validate the definition and outcomes of refractory DLBCL in China,we conducted a multicenter,retrospective cohort study.Methods:The REtrospective AnaLysis of Treatment REspoNse of refractory DLBCL(REAL-TREND)study was performed using real-world data from 8 centers in China.DLBCL patients with curative intent were included in the REAL-TREND dataset.Overall survival(OS)was estimated using the Kaplan-Meier method and compared by the log-rank test.Due to heterogeneity in response rates among different centers,the response rates of refractory patients were pooled using random-effect models.Multivariate survival analysis was performed using the Cox regression model.Results:A total of 2778 DLBCL patients diagnosed between January,2010 and December,2015 were enrolled to this study.After validating previous definitions,the SCHOLAR-1 study was most suitable to define refractory DLBCL.The estimated 5-year cumulative incidence of refractory patients was 20%(95% confidence Interval[CI]=18%-22%).After the determination of refractory disease,overall response rate and complete remission rate were 30%(95%CI=22%-38%)and 9%(95%CI=4%-15%),respectively.Patients with either no response to immunochemotherapy or relapse within 12 months after stem-cell transplantation had inferior survival with a median OS of 5.9 months(95%CI=5.5-7.1 months)and 2-year OS rate of 16%(95%CI=12%-20%).International prognostic index score 4-5(hazard ratio[HR]=2.22;95%CI=1.47-3.35),central nervous systemrelapse(HR=1.43;95%CI=1.04-1.97),and best response status(HR=2.68;95%CI=1.42-5.03 for partial remission.HR=5.97,95%CI=3.21-11.11 for stable disease/progressive disease)were independent unfavorable prognostic factors.Conclusions:This is the first large-scale Asian cohort study focusing on outcomes of refractory DLBCL.The definition of the SCHOLAR-1 study identifies patients with homogenously inferior survival,thus is appropriate to select refractory DLBCL.Due to poor clinical outcomes in the rituximab era,patients with refractory DLBCL may be potential candidates for novel treatment modalities.